Observational Study to Evaluate the Safety and Efficacy of Levemir® in Type 2 Diabetes

Assessment of Safety and Efficacy of Levemir® (Insulin Detemir) Treatment for Insulin Naive Patients With Type 2 Diabetes Mellitus

This study is conducted in Africa. The aim of this study is to assess the safety and efficacy of Levemir® treatment for insulin naive patients with type 2 diabetes under normal clinical practice conditions in Algeria.

Inclusion Criteria:

• Informed consent obtained before any trial-related activities
• Type 2 diabetes
• HbA1c between 7-9%
• Insulin naive
• Inadequate control with oral antidiabetics therapy as judged by investigator

Exclusion Criteria:

• Patients with type 1 diabetes
• Hypersensitivity to Levemir® or to any of the excipients
• Pregnancy, or desire of pregnancy within next 6 months
• HbA1c greater than or equal to 9%
• Known or suspected allergy to the trial product or to any of the excipients
• Subjects who are unlikely to comply with protocol